Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.55 |
| ▸ | FABP1 | P07148 | 4/20 | 0.49 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.48 |
| ▸ | FABP4 | P15090 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29726979 | 1.00 | NR1H4 (0.55) | NR1H4FABP1HSD17B13FABP4 | |
| SCHEMBL23474126 | 0.90 | NR1H4 (0.57) | NR1H4FABP1HSD17B13FABP4 | |
| SCHEMBL23474125 | 0.83 | NR1H4 (0.49) | NR1H4FABP1HSD17B13FABP4 | |
| SCHEMBL23480618 | 0.82 | NR1H4 (0.48) | NR1H4FABP1HSD17B13FABP4 | |
| SCHEMBL28728433 | 0.81 | NR1H4 (0.53) | NR1H4FABP1 | |
| SCHEMBL29467359 | 0.81 | NR1H4 (0.53) | NR1H4FABP1 | |
| SCHEMBL24741319 | 0.80 | NR1H4 (0.48) | NR1H4FABP1HSD17B13FABP4 | |
| SCHEMBL23474178 | 0.79 | NR1H4 (0.58) | NR1H4HSD17B13 | |
| SCHEMBL23480863 | 0.78 | NR1H4 (0.49) | NR1H4FABP1HSD17B13FABP4 | |
| SCHEMBL23474150 | 0.78 | NR1H4 (0.54) | NR1H4FABP1HSD17B13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165843-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | GANNEX PHARMA CO LTD (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230165843-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | GANNEX PHARMA CO LTD (CN) | 2023-06-01 | — | — | US | disclosed |
| CN-112898289-B | Compounds for modulating FXR activity and uses thereof | 甘莱制药有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-112891348-B | Use of phenyl isoxazolyl methylene-naphthalene-ether derivatives and pharmaceutical compositions | 甘莱制药有限公司 | 2022-06-28 | — | — | CN | disclosed |
| WO-2021108974-A1 | COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF | GANNEX PHARMA CO., LTD (CN) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021109713-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | GANNEX PHARMA CO., LTD. (CN) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021109712-A1 | COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF | GANNEX PHARMA CO., LTD. (CN) | 2021-06-10 | — | — | WO | disclosed |
| CN-112891348-A | Use and pharmaceutical composition of phenyl isoxazolyl methylene-naphthalene-ether derivatives | 甘莱制药有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-112898289-A | Compounds for modulating FXR activity and uses thereof | 甘莱制药有限公司 | 2021-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165843-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | VIM, CYP3A7, HAVCR2 | NR1H4 116/4885FABP1 39/4885HSD17B13 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.